Accenture invests in Earli to boost early cancer detection
NEW YORK and CALIFORNIA, UNITED STATES — Outsourcing giant Accenture has made a strategic investment in Earli Inc., a biotechnology firm based in Redwood City, California, known for its innovative approach to early cancer detection.
This investment, made through Accenture Ventures, aims to enhance collaborations with global health and pharmaceutical companies by leveraging Earli’s unique technology, which could improve the accuracy and speed of cancer diagnosis and treatment.
Revolutionary synthetic biopsy technology
Earli has developed a synthetic targeting platform that reprograms cancer cells to reveal and destroy themselves.
This approach uses programmable genetic constructs to signal the presence of active cancer cells at an early stage, enhancing the sensitivity and specificity of cancer detection.
The technology has the potential to discover multiple types of cancer through non-invasive screening techniques, including blood samples and PET scans, even detecting tumors too small for existing methods.
“Earli’s synthetic biopsy method is a step change in early cancer detection technologies and will offer significant advantages to biopharma companies by improving the precision and efficacy of new treatments and diagnostics, as well as in understanding the mechanisms of cancer progressions,” said Petra Jantzer, senior managing director and global lead of the Accenture Life Sciences business.
Expanding global healthcare capabilities
The investment is part of Accenture Ventures’ Project Spotlight, an engagement and investment program that provides startups with access to Accenture’s domain expertise and enterprise clients.
This collaboration aims to advance capabilities in cancer research, drug development, and patient care within the biopharma industry.
Cyriac Roeding, Co-Founder & CEO of Earli Inc., expressed enthusiasm about the partnership: “Accenture’s impressive network of biopharma clients will be very impactful for Earli. It is fantastic to have Accenture support our mission to make cancer a benign experience.”
Tom Lounibos, global lead for Accenture Ventures, noted, “With Earli joining our Project Spotlight program, we can collaborate with our clients in the biopharma industry to advance their capabilities in cancer research, drug development, and patient care.”
Other biotechnology companies that have joined Project Spotlight include Turbine, QuantHealth, Virtonomy, and Ocean Genomics.
Accenture is a global leader in professional services. It operates in more than 120 countries and has an approximately 750,000-person workforce. For the second consecutive year, it ranked #1 in the OA500 2024, an objective index of the world’s top 500 outsourcing companies.
